Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 92,942	$ 106,084
Short-term investments	149,877	264,984
Restricted cash	146	194
Accounts receivable	40,221	986
Inventories	1,586	0
Other current assets	10,308	12,373
Total current assets	295,080	384,621
Property and equipment, net	6,300	53,780
Operating lease assets	68,022	26,159
Restricted cash - long-term	0	1,200
Other assets	7,018	2,367
Total assets	376,420	468,127
Current liabilities:
Accounts payable	6,871	17,368
Accrued compensation	17,659	25,150
Accrued research and development expenses	24,992	13,451
Deferred revenue	8,000	40,760
Other current liabilities	21,394	9,057
Total current liabilities	78,916	105,786
Deferred revenue - long-term	77,000	55,708
Operating lease liabilities - long-term	58,064	25,518
Liability related to the sale of future royalties - long-term	30,236	0
Other long-term liabilities	5,564	1,501
Total liabilities	249,780	188,513
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock-$0.0001 par value, 500,000 shares authorized as of December 31, 2022 and 2021, respectively; 95,927 and 91,671 shares issued and outstanding as of December 31, 2022 and 2021, respectively	10	9
Additional paid-in capital	1,821,721	1,744,695
Accumulated other comprehensive (loss) income	(2,067)	(368)
Accumulated deficit	(1,693,024)	(1,464,722)
Total stockholders’ equity	126,640	279,614
Total liabilities and stockholders’ equity	$ 376,420	$ 468,127